. M :\-lush_v
`.i r‘.) ’4‘?
`
`VOLUME 117 No. 4
`APRIL 2006
`wwwjacionlinaorg
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CASE STUDIES
`TACI mutation with invasive poiycionai
`(08* f-caii iymphoproiiferatian in a patient
`with CVI'D
`
`
`
`Etanercept treatment of cutaneous
`gronuiomos in C VID
`WORKSHOP SUMMARY
`Prima
`immunodeficiency diseases:
`An smite from the iU'tS, Budapest, 2005
`CLINICAL PEARLS
`Primary immunodeficiency or not? Making
`the cormt diagnosis
`AUERGY ARCHIVES
`Henry N. Ciamon. MD: Ceiiuiar cooperation
`in antibody production
`
`CURRENT REVIEWS
`The Wiskott~Aidricb syndrome
`MOlECUMR MfCHANiSMS
`Molecular basis of common variabie
`immunodeficiency
`EDITORIAL5
`
`"1e last 80 years in primary
`immunodeficiency
`Navigating today's success to prepare for
`tomorrow's exploration
`CURRENT PERSPECTIVES
`Defects ot' clots-switch recombination
`
`Gene therapy for immune disorders
`
`m1
`
`\I'i\IYl‘I .-\].[H\'LIY
`\t
`1.x.
`3;::
`\_~|i:“-\1\\\ 121w m mm
`
`Page 1 of 16
`
`CSL EXHIBIT 1009
`
`Page 1 of 16
`
`CSL EXHIBIT 1009
`
`

`

`THE JOURNAL OF
`Allergy...” Clinical
`Immunology
`
`(mil
`VOLUME H7 ' NUMBER 4
`ASTHMA s IMMUrs'ouxa‘
`
`AMERICAN ALLADhMY oi ALLhIim
`
`OFFICIAL JOURNAL or m: AMERICAN ACADEMY or ALLERGY, ASTHMA AND IMMUNOLOGY
`
`
`
`About the cover
`
`* 'I‘Iiis nmnlh'x theme: Update on primary immunodeficiency
`
`Cm'm‘ design by JD], LLC.
`
`The front coverofthis issue ofthc Joumal pays tribute to the progress in
`primary immunodeficiency that has been made in the past 80 years. The
`artist presents the world of primary immunodeficiency that appears in all
`populations of people in every country with representative images of
`patients. one (left) with ataxia tclangiectasia first described in 1926. and
`another today (rig/H; with X—linked severe combined immunodeficiency
`(SClD). Shown also are the healing hands ofmedieine that provide patient
`care. education. and research support for patients with primary immuno-
`deficiency (see also Fig l
`in the Editorial in this issue by Shearer and
`Fischer. pp 748-52). In the span of 80 years we have come from the time
`when only the clinical phenotype of immuntxicticiency could be de-
`scribed. to the present when not only detemtination ot' the genotype of
`immune diseases can be accomplished but the correction of faulty genes
`as well. Thus. formerly. the patient with ataxia telangiectasia received
`only supportive care. whereas today the patient with X-linlted SCID is receiving an infusion of his own hone
`man'ow—dcrivcd stem cells into which the nomial gene for the lL-2R7 chain gene has been inserted (courtesy of
`Drs Harry Malcch and Jennifer Puck. National Institutes of Health. Bethesda. Md). Considering the spectacular
`jountcy of the past 8 decades. one must ask. "Where will the next 80 years take. us?"
`The update on primary iInrnunodeticiency featured in this issue is presented in several reviews. features. and
`original aniclcs that are noted in the Table of Contents by a red starhurst beside their titles. We thank Associate
`Editor William T. Shearer. MD. PhD. for developing this excellent theme issue.
`
`
`
`This month in Beyond Our Pages
`
`
`The distribution in the peripheral airways of inhaled ll-agonists of various particle sizes was compared with the
`bronchodilating effects of such preparations. 0 Encouraging findings in large studies of 2 new rotavirus vaccines
`have been reported. I A large epidemiologic study compared the association of endotoxin exposure and asthma
`prevalence. 0 Another study explored mechanisms involved in the recruitment ot'eosinophils to the area of airway
`nerves. 0 An investigation showed that missense mutations might lead to altered function of perforin. a protein
`involved in cytotoxic defense mechanisms. leading to certain diseases. 0 Studies in a murine transgenic model
`support the view that basophils have art important primary role in chronic allergic inflammation.
`
`© 3006 American Academy u} Al/ergr, rill/Ulla um! lIiImImo/ogr
`
`Tin Journal of 'i/lt'l'_t!_\ mitl ('Iim't HI Immmm/uet- IlSSlN “(NP/70740: is published Innltthl) I I: Issues per year: by Elscuer lnc . 3!)“ Park Avenue South. Veu
`York. NY Itltltt-I'I‘IO. Business and Editorial Utltces
`tom John |- Kennedy Boulevard. Suite IXtIi. Philadelphia. PA [9103-1890 Accounlmg and
`Circulation Offices
`1:277 §ea Ilzirhnr Drive. Orlando. H. 318x7-JKtKI.
`l’ctiudrcals postage [Mid .II Orlando. Fl. 52%: and additional mailing offices.
`PUS'I MAS I'ER Send address changes to [We Journal of Mint-i um/ ('tI'Irr'I HI Int/Intuition tlwvici i‘criodu .Ils ('ustomer Sen IkL‘. (i377 Sea llarbot Dr'nc.
`Orlando. tL 528K748“)
`
`J ALLERGY CLlN IMMUNOL
`
`April 2006
`
`5A
`
`Page 2 of 16
`
`Page 2 of 16
`
`

`

`In
`.0—
`
`- C OU
`
`Coo
`
`I lI
`
`‘
`
`723
`
`725
`
`739
`
`740
`
`747
`
`748
`
`753
`
`756
`
`CONTENTS
`
`The editors’ choice
`
`Donald Y. M. Lang. MD. PhD. Harold 5. ermn. A40. and Stanley /. Szeflzr. Ml)
`
`Reviews and feature articles
`
`Current reviews of allergy and clinical immunology
`
`Ham D. Orin. MI). and Adrian j. Tomi/Mr. MD. PM). Sam/t. War/J. and lorulun. Um'ml Kingdom
`
`Continuing Medical Education examination: The Wiskott-Aldrich syndrome
`
`TheWiskott-Aldrichsyndrome
`
`* Molecular mechanisms in allergy and clinical immunology
`Molecular basis of common variable immunodeficiency
`Emanueh Camgli. DSr. and RaifS. Calm, MD. Boston. Mow
`
`Continuing Medical Education examination: Molecular basis of common
`variable immunodeficiency
`
`Editorials
`
`* The last 80 years in primary immunodeficiency: How far have we come,
`how far need we go?
`William T.
`.S'lttarrr. MD. HID. and Alain Hither. MD. I’IID. Harmon. Ta. and Pam. Franrr
`
`Navigating today's success to prepare for tomorrow’s exploration
`Donald Y. M. bung. MD. [’50. Nancy 7: Hopper. BS. AM. and Terr-k DuHAu/tmy. Denver. Cola and St Lomr. Ala
`
`Clinical pearls
`
`* Primary immunodeficiency or not? Making the correct diagnosis
`Rebeca: H. Buckley. Ml). Dar/mm. N(,
`
`
`
`Continued on page 9.4
`
`The Journal of Allergy and Clinit‘ul Inmmnulog)‘ posts in-press articles online in advance of their appearance
`in the print edition of the Journal. They are available at the JACI Web site at www.jacionline.org at the “Articles in
`Press“ link. as well as at Elscvier‘s ScienceDirect Web site. www.5ciencedirect.com. Each print article will
`acknowledge the c-publication date (the date when the article first appeared online). As soon as an anicle is
`published online. it is fully citable through use of its Digital Object Identifier (DOI). Please visit the JACI Web site
`and view our hot-off-the—wire articles through the “Articles in Press" link.
`
`* CME examination article available online at wwwjacionlineorg
`
`Q Editors’ Choice (p 725)
`
`® Online Repository material
`* Theme issue
`
`J ALLERGY CLIN IMMUNOL
`
`April 2006 7A
`
`Page 3 of 16
`
`Page 3 of 16
`
`

`

`Wo
`
`- Cd
`
`)o-
`
`C OU
`
`CONTENTS
`
`CONTINUED
`
`Asthma diagnosis and treatment
`
`Original articles
`
`6 Accuracy of US Food and Drug Administration—cleared lgE antibody assays
`in the presence of anti-IgE (omalizumab)
`[in/"r! G. Nomi/Inn, Phi). DAHMLI. linliimurr. Md
`
`759
`
`in serum
`the presence of omalizumab (Xolait: anti—human lgE)
`This study finds that
`degrades the accuracy of most US Food and Drug Administration—cleared total and
`:dlcrgen-specific lgE assays used in clinical
`immunology laboratories; however.
`the
`lmmunoCAl’ is designed to accurately quantify levels of total and allergen‘specific 1in
`in human serum containing therapeutic levels ofomalizumab.
`
`@ Bronchial challenges in athletes applying to inhale a BZ—agonist at the 2004
`Summer Olympics
`.Stmdm I). Andmun. PM). USr. Malta/m Sur-C/m. AIB CAB. P/ID. Clare P. Perry, 854'. Dip Ell, Christina
`(int/Zion. MI). HID. Pram/e Kip/trim. I’IJD, I)(m C. Alrlt'mzir, MD, PhD, Km C. Heck, PhD. and Kn! D. Fire/I.
`M8115. Ml). (Jim/indium and tN’rr/ldmit. Autrnrlm. Trend/trim. Norway. Alht‘lll, (inert.
`l'iinrnuL-(r. Briuch
`(Columbia. (Jmadu. and SI Paul. Minn
`
`767
`
`This study is a summary of the objective evidence submitted on athletes for the Summer
`Olympic (James to justify the use ofan inhaled liz—agonist prior to an event.
`It is of clinical
`importance that athletes with lung function well within the healthy range have such marked
`bronchial
`llypcrresponsiveness and suggests that many athletes with asthma are being
`undertteated.
`
`Mechanisms of asthma and allergic inflammation
`
`Association between genetic variations ofvascular endothelial growth factor
`receptor 2 and atopy in the Korean population
`Hams-“"1“; l’url'. A‘lI).jt'Iltgv/:‘IHI La. l’lrl). [INFSUUU Shirt, I’ll/l [1M Young/1t. Mar/mm- Woo Bit/m, Ml). “tung-
`Iilml (M. [\II)‘ Nam Yrumg ”/1, Phi), hing-Hm" (.710. All). Her-Bum t'rlmm. 1W1), Kyungdl/v Aim. All). lurk/l
`15/1115. MD. Mir-Young Kim. MD. and Your) Km" Kim. All). Seoul rind KyunggiI/o. Korea. mu]
`New Hmvnl. (:1qu
`
`774
`
`This is the litst report demonstrating that genetic variations of vascular endothelial growth
`factor (VEGF) receptor 2 are significantly associated with atopy in the general population
`and also among asthma patients. This result
`implies that VEGF signaling pathways are
`involved in the genetic predisposition to atopy.
`
`® Reduced airway hyperresponsiveness and tracheal responses during allergic
`asthma in mice lacking tyrosine kinase inducible T—cell kinase
`lhnnu /, Frmrm. M). Cyril/1m Marl/(r. MN. Nitrlnm Ail/m. Mé.
`.‘lbdrllazrz Ben—,Irbrm. l).\t'. and
`Anny Augml, I’M}. Unirrmry I’urlr, Pr,
`
`780
`
`This aniclc provides evidence for a prominent role for T-t'ell—exprexsed Tec family tyrosine
`kinase inducible T-cell kinase (ITK)
`in the modulation and development of airway
`liypertesponsiveness.
`tracheal responses and lung T”2 cytokine production in a murine
`model of allergic airway disease. The results in this article suggest that efTorts to target lTK
`pliarmaceutically might he beneficial in reducing allergic airway responses.
`
`J ALLERGY CLIN IMMUNOL
`
`Page 4 of 16
`
`Continued on page I IA
`April 2006 9A
`
`Page 4 of 16
`
`

`

`Ina-
`
`C d
`
`)4-
`
`
`
`C OU
`
`
`787
`
`
`CONTENTS
`
`CONTINUED
`
`
`
`
`
`
`
`
`
`
`
`
`Airway epithelial cells produce neurotrophins and promote the survival of
`
`
`
`
`
`eosinophils during allergic airway inflammation
`(.‘ltrirrirm Helm. PhD, Anya" I’imyesh Islamian. Hamid Razz, MD. and Wolfgang Andrea: Nnrkbrr, MD, MSr,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mirrburg. Germany
`
`
`
`
`
`Neurotrophins contribute to eosinophil—epithelial cell interactions during allergic airway
`
`
`
`
`
`
`
`
`inflammation through upregulation of epithelial neurottophin production and pro-
`
`
`
`
`
`
`
`
`longation of tissue eosinophil survival. Inhibition of increased epithelial neurotrophin
`
`
`
`
`
`
`
`
`
`production might be an important target to control the allergic airway eosinophilia.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`® lL—17F sequence variant (Hisl6lAtg) is associated with protection against
`
`
`
`
`
`
`
`
`
`
`
`795
`
`
`
`ll
`
`‘
`
`
`
`
`
`
`
`
`
`
`
`
`
`asthma and antagonizes wild—type IL—17F activity
`M'ia Kawagur/ii. MD. Drusmir 7k§m9ruiii MD. Nahuywii Himwtz. MD. Skintam Suzuki, MD. Sararhr‘
`
`
`
`
`
`
`
`
`
`
`
`
`
`r'lfzmmi’urrr. 1WD. Fumin kbii'ulrm. IUD. Yupl'iko fllnm'a. MD. Ynjfii'nabu le'm'. All). Semi/yr Karma. IUD. Slrau-[i’lr
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`I’IJD. Marathon: Nubirmml, MD. and Mirrum Adarlii, MD, Tori-yo and Sapporo, japan. and Hairimarr, Md
`Huang.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`is inversely associated with
`lL—l7l: variant. which antagonizes wild—type IL—17F activity,
`
`
`
`
`
`
`
`
`
`
`asthma, suggesting a role For lL—17F in the pathogenesis of asthma, and a therapeutic utility
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`of targeting lL-17F activity.
`
`
`
`
`
`
`
`
`
`
` Rhinitis, sinusitis. and ocular diseases
`
`
`
`
`
`
`
`
`
`@ Sublingual immunotherapy with once—daily grass allergen tablets: A random—
`302
`
`
`
`
`
`
`
`ized controlled trial in seasonal allergic thinoconjunctivitis
`Stephen R, Durham. MU. William H. Yang. MD. Martin R. Peder-rm, MSr-lerm, Nirbjahamm. MSr-Cfarm Eng. and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Sabina Rafi. MD. London. United Kingdam, Ottawa. Ontario. Canada. Hats/Joint, Denmark. and Giteborg. Smdm
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Specific immunmherapy For allergic disease. although effective, might be associated with
`
`
`
`
`
`
`
`
`
`
`
`serious side effects as a rESulr of being delivered by injection. Suhlingual immunotherapy
`
`
`
`
`
`
`
`
`
`
`
`
`
`reptesen [8 an alternative treatment that can relieve symptoms with an improved safety profile.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Double—blind, placebo-controlled study with a modified therapeutic vaccine of
`
`
`
`
`
`
`
`
`
`
`5415014 km’i (Russian thistle) administered through use of a cluster schedule
`Carlo: Cain's. MD. Phi). Susana Alonzo". 1WD. HID, Aldrin}: Venturim, JWD. and Apalinnr Lemon, MD, PhD.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Zamgazu. hymn:
`
`
`that
`report
`immunotherapy with a depigmented and glutaraldehyde—
`The authors
`
`
`
`
`
`
`
`
`
`polymerized extract of 5415011: [Bali pollen is safe and el'Tective in the treatment 0F patients
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`clinically sensitive to this pollen.
`
`
`
`
`
`
`
`
`
`
`810
`
`
`
`Environmental and occupational respircfloryr disorders
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`@ Prenatal farm exposure is related to the expression of receptors of the innate
`
`
`
`
`
`
`
`
`® immunity and to atopic sensitization in school-age children
`Afarltusjafi'immr: 1:39.
`.MD, Christian Biei'i, MD. Rzmo Fiw'. M511 Robert Tbtodaor Uflfl Strit'n, PhD. jareflr‘irdlzr,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MD. [film Ubbz‘ggzr. MD. Dimrkr .S'rfrmm—Bg'krrk.
`.MS'r. Herr Brunrkrerfl PhD. Mariam” mm Huge, MD. PhD.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`.‘llmikrz Stirqvnim. 1WD. P/JD. Gareth Peri/mgr”. :1”). PhD. [Worms R. Brnz. MD, Roger Lam-"n. MD. Erika van
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Marius, MD. Chariot” ”qu’irll‘fl/JP'IJHII'KK MD. and the PA RSIFA L Study ream. Mimirb, Gmnany. Barr! and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`[um-.9. Switzerland, Srfrwflrzrlrl') and Salisbury. Auntie. Utm‘hr, Tbr Net/101mm}. and Starkhrt/m. Sweden
`
`
`
`
`
`
`
`
`
`
`
`
`Maternal exposure to environments rich in microbial compounds is inversely associated
`
`
`
`
`
`
`
`
`
`
`
`with the risk of atopy and increases gene expression of receptors of the innate immune
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`system in the offspring. This article highlights the importance of prenatal environmental
`
`
`
`
`
`
`
`
`
`
`
`
`exposures for the development of allergic diseases.
`
`
`
`
`
`
`
`
`
`
`817
`
`J ALLERGY CLIN IMMUNOL
`
`
`
`
`
`
`Page 5 of 16
`
`
`
`
`
`Continued on page [JA
`April 2006 11A
`
`
`
`
`
`Page 5 of 16
`
`

`

`CONTENTS
`
`CONTINUED
`
`® Effects of ulttafine carbon particle inhalation on allergic inflammation
`of the lung
`I‘TINIl'f’Jt'll A/rmmr/rmi, PM), Halger Srimlz, MD, Shin}: Tirl'nmka. DH”, I’M). Brrml' 1mm”. BSt‘.
`Erwin ng. Mgr. [It‘ll/"III Brltrmtlr. AID,
`.md' T/Ji/t/ Mimi). 2WD. Nru/Jrrhrrg and .Munu'lr. (irrnunry
`
`This article evaluates the effects of inhalation of elemental carbon ultrafine particles
`(EC-UFP] on the allergen-induced inflammation of the lung. EC-UFP inhalation prior
`to allergen challenge dramatically augments
`the allergic inflammatory response (as
`documented by increased btonchnaleveolar lavage cellular infiltrate. bronchoalveolar lavage
`fluid cytokines, and airway liyperreactivity), whereas EC—UFP inhalation during an ongoing
`allergic inflammation does not. Allergic sensitization might thus represent a susceptibility
`{actor for the effects of UFP on allergen—induced inflammation of the lung.
`
`
`
`824
`
`Effect of codeine on objective measurement of cough in chronic obstructive
`pulmonary disease
`liar/y” Sum/J, AND. HID. Emil) Owen. 1W]’lnl. Vlu/tn Eitm. MI). and AMA]! Wimdmrfi. MD. Mane/utter rmr/
`Llrrrpoal'. Uliirrr/ Kingdom
`
`831
`
`Codeine is the standard antitussive agent [0 which novel treatments are compared. In this
`double-blind. randomized control trial, codeine had no significant effect over placebo in
`patients with chronic obstructive pulmonary disease with chronic cough.
`
`Food allergy, dermatologic diseases, and anuphylaxis
`
`a Cathelicidin deficiency predisposes to eczema herpeticum
`Mir-burl l). How/1. I’M). Andrea's W'o/Irnbng. MD. Richard L Cal/o. 1WD. PhD. Mir/1M! Fizrrg, MD. 10:")an
`Srrei/L 8/! Cathy Wong. HS. Tarjaml I’twim'. Ml). Mark Buguriim'im All). and Dorm/II Y. 5!. Ltuvrg. .MD. PhD.
`Drum. (.blo. Aluuir/J. (Trrmmiy, mid San Dirge, Ctr/if
`
`836
`
`This study demonstrated that the naturally occurring antimicrobial peptide LL-37 kills
`herpes simplex virus. Furthermore. a deficiency of LL-37 might predispose this population
`of patients to eczema herpeticum and this might correlate with serum lgE.
`
`Skin prick test to egg white provides additional diagnostic utility to serum eg
`white—specific IgE antibody concentration in children
`I'll”)!!! Kay Knrg/Il. A”), Wayne (1'. Slimmer. (WI). I’hl). Hugh/4. Sampson. .410, Sea" H. Sit/Mr”. 1WD,
`Sn/[y NIHIIK’. RN. MSN. S/ua'rh Mafirll. AIS. RD,
`(LS'I’. um! rlmm Nuuurk- W’rgrzyu. MD. New York. NY
`
`842
`
`The size ol‘ egg white skirt prick test wheal might provide the clinician with additional
`information to determine the timing of egg oral food challenge in children with low egg
`white~speciiic lgE antibody level.
`
`® Molecular cloning and expression in insect cells of honeybee venom allergen
`acid phosphatase (Api m 3)
`Tlmmtu (Irmm'ttld, I’IJD. Berymnm Berlin/J, P/JD. Edzan/ Spit/n”. PhD. [alvmnm Ring. MI). PM).
`It‘rinlnnd [halt/writ, MD. and .Urrr/zrn‘ W" ()llrrr. Ml). Hamburg mu! [Mimir/i. ({rmmlry
`
`848
`
`a new tool might be available to facilitate the
`that
`The authors” findings suggest
`development of improved diagnostic tests as well 15 the design of safer and more elfective
`immunothempies for honeybee venom allergy.
`
`J ALLERGY CLIN IMMUNOL
`
`Page 6 of 16
`
`Continued on page MA
`April 2006
`13A
`
`

`

`855
`
`
`
`
`865
`
`870
`
`
`
`
`CONTENTS
`
`CONTINUED
`
`
`
`
`
`
`Basic and clinical immunology
`
`
`
`
`
`Cu rrem perspectives
`
`Defects of class-switch recombination
`
`
`
`
`Luigi D. Nrimrangeln, MD. Gasman [AMA PhD. Sap/Jig Percy, and Armr- Durand}, MD. I'IJD,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Brem'a.
`limb. and Parir. Frame
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Gene therapy for immune disorders: Good news tempered by bad news
`jcnmfrr M. Park, MD. and Harry L. Mainly. MD. Hrrlmdd. Mr!
`
`
`
`
`
`
`
`
`
`
`Case studies
`
`
`
`
`
`n O3-
`
`p
`(D
`3
`j -l-
`U!
`
`
`
`
`
`
`
`
`
`
`
`* TACI mutation with invasive poiycional CDB+ T-cell lymphoptoliferation in
`
`
`
`
`
`
`a patient with common variable immunodeficiency
`Luanda ]. Bergl'rmd. MBES. Graham], jrrrm'. 53:. PhD, Rajmahan Murrrl'r, M'BBS. and Drmui A. Fulrrlrrr. MBBS.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`PM). Sydney. Australia
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`* Etanercept treatment of cutaneous granulomas in common variable
`
`immunodeficiency
`farm” H. Lin. MD, Myron Lieblmber, MD. Robert L. Robyn. .MD, I’M). Zeb Dyrr. P11.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`E. Rirhard .S'rrebm. MB. L0: Angels: and Santa Barbara. Calif
`
`
`
`
`
`
`
`
`
`
`
`:mra’
`
`
`
`
`
`878
`
`
`
`‘
`
`i-
`
`
`
`
`Workshop summary
`
`
`
`
`
`
`
`
`
`
`
`* Primary immunodeficiency diseases: An update From the International Union
`
`
`
`
`
`of Immunological Societies Primary Immunodeficiency Diseases Classification
`
`
`
`
`
`Committee Meeting in Budapest, 2005
`Luigi Nararangda, MD. jean—Lauren: Gamma/a. MD. Mary Him Conley. AID. Hrlm Chapel. 1WD. Alain Fischer.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MI). jennifir Park. MD. Chaim waman. MD. Reinhard Segrr. MD. and Rm'fS. (fr/m. MD.fbr :5: International
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Union qf'lmmmralagiml Sarittir: Primary innmmm'rfirirmy Diseases (lirrffirazitm fiammirrrr. erin, hair. Parr}.
`
`
`
`
`
`
`
`
`
`
`
`
`Frame. Memphis. Term. Oxford, Unirra' Kingdom, Bethesda. (Md. Toronto. Omar—in, Canada. Zurich. Hwimr/dnd',
`
`
`
`
`
`
`
`
`
`
`
`
`
`and Boston, [Mun
`
`
`
`
`
`
`
`
`
`Original articles
`
`iseast
`
`
`
`
`
`
`
`
`
`
`Mutations in the RNA component of RNase mitochondrial RNA processing
`
`
`
`
`might cause Omenn syndrome
`Clmim M. Rurfinau, MD. FRCPC. Yiping Cu. 83:", mm' Amos (.‘ar‘im.
`
`
`
`
`
`
`
`
`
`
`
`
`l’l'u'). Tanmm, Ontario. Canada
`
`
`
`
`
`
`
`This report shows For the first time that mutations in the RMRI’ RNA gene. which are
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`known to be associated with cartilage—hair hypoplasia. might cause Omenn syndrome.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Self-administration ofCl—inhibitor concentrate in patients with hereditary
`
`
`
`
`
`
`
`or acquired angioedema caused by Cl-inhibitor deficiency
`Man's! Levi. MD, Gain: Char, MD, Charles Pimvet. MA, and C. Err} Hack. MD. Amsterdam, Thr Nelhcrlantlr
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Self-administration of CI-inhibitot concentrate. as reported in this article, saves valuable
`
`
`
`
`
`
`
`
`
`
`time and resuits in early relief and complete resolution of angioedema symptoms and in
`
`
`
`
`
`
`
`
`
`
`
`
`
`prevention of angioedema attacks in patients using the concentrate as prophylaxis.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`883
`
`
`
`
`897
`
`904
`
`
`
`14A April 2006
`
`
`
`
`
`Page 7 of 16
`
`
`
`
`
`Conrimted on page 16A
`J ALLERGY CLlN IMMUNOL
`
`
`
`
`
`
`Page 7 of 16
`
`

`

` Association of CD4' T-lymphocyte counts and new thymic emigrants
`
`CONTENTS
`
`CONTINUED
`
`909
`
`in HIV—infected children during successful highly active antiretroviral
`therapy
`Al'i/Jika Sunni). AID. Kumud K. Sing/t. I’M). Miami Sandal/1. 3.5. (.7vritriril 1“ Powell. MA. Invent-r Fmtnn, Fall).
`(Touring V. Flat/m. PhdrntD, Kan-n HJIII. I’M).
`:17"! Sir/Jun A Spa-tar. MI). [.4 loll/I. Cal/f Basia". Mao. and
`Dawn C0141
`
`T-cell receptor excision circle (TREC) levels correlate with HlV—l intracellular DNA levels
`and CD4‘
`'l‘-lymphocy‘te counts in HlV-l—Inlected children receiving highly active
`antiretroviral therapy with sustained viral suppression.
`
`916
`
`Decreased CD4' lymphocytes and innate immune responses in adults with
`previous extrapulmonary tuberculosis
`Paulo R. Z. Anliu. P/JD. Lt Dang. AID, judn/a Hm‘kmdn. RN. Linda Ruin-Hammm'l‘. RN. Ayumi K. Vunum.
`I’M). [WP/I. jail!“ .S'z'luflrr. MD. Strum M, Ila/land. MD. um! Timur/{y R. Strrlmg. AID.
`inlJ/Jl'l’lfi
`lrnn. and
`Berlmrla and Bd/IIMIN'I. All!
`
`i ®
`
`Compared to persons with cured pulmonary tuberculosis or Abrobanmum tu/tm‘ulasir
`infection. HlV-setonegative adults with cured extrapulmonary tuberculosis had lower CD4"
`lymphocytes and unstimulated cytokine production. suggtating ahnormal
`innate immune
`function.
`
`Leukotriene D4 enhances immunoglobulin production in CD40—activated
`human B lymphocytes
`lmér Ianwurrux. [’60. [mm Sankara. PhD. and Marti Rnla-I‘lrxa-zvmh. MI), .Vtrr/trnnl-r. Quelm, Lari/111a
`
`924
`
`Stimulation ofhuman B lymphocytes with (1740 ligand in conjunction with ll.-~) enhances
`their expression ol'CysLTl and this is associated with increased responsiveness ofthc cells to
`LTD‘ in terms of calcium mobilization and lg production.
`
`® Associations of cord blood fatty acids with lymphocyte proliferation.
`[1:13. and lFN—y
`Dian! l\'. ( [0/11. MD. MPH. Hm M.
`\Vi/Iu‘rnlv. MI). .‘ISr. Kr/Jn (ii. Tauutmt, MI). I’umrm ll" Finn, MI). Ill-mm
`Stlhlub. MD. Dali/id L I’erkim. All). I’M). Arthur Ithnubm. I‘l/D, A'gur l’. L). Ml). (Jimmy: Xi'lrrnrlrr. MI).
`Fiona (v'IMurm. MD. HJnnia (hm/W. AID. Emily (Mm. MD. NIP”. Man/mil W'.
`till/1mm. Ml) 5M,
`Ly]: I.
`l’ulmrr. I’ll/3. [mun 41!. Ryan. P/ID. and 5.1;” I. Who. .1”). Hyman. Man
`in cord blood. elevated levels of n-3 cicosapentaenoic acid and n-(i arachidonic acid were
`associated wrth attenuation of lymphocyte proliferation and lFN-y production.
`implica-
`tions of these findings for allergy or asthma development are nOt yet known.
`
`931
`
`® lgE memory: Persistence ofantigencspecific lgE responses years after treatment
`of human filarial infections
`Edward Mitre. MD. and Thoma.) If. Ntmmm MD. [tn/mild. MM
`
`939
`
`This study demonstrates long-term persistence of parasite-specific lgE responses in humans
`in the absence of reexposure to pathogen. Clinically. these findings suggest that absolute
`allergen avoidance might not result in the loss of allergy. and parasite-specific lgEJnducing
`vaccines. if effective. could potentially induce longstanding protection.
`
`l
`
`‘
`‘
`
`il
`
`
`
`16A April 2006
`
`Continued on page 18A
`J ALLERGY CLIN IMMUNOL
`
`
`
`Page 8 of 16
`
`

`

`CONTENTS
`
`CONTINUED
`
`Letters to the Editor
`
`Quantitative assessment of the compliance with a once—daily sublingual
`immunotherapy regimen in real life (EASY Project: Evaluation of A novel
`SLIT Formulation during a Year)
`Giovanni Paxsabtqua. Ml). Ammmm Alumna. Ml). Silvia I’tmm. AID. Sart‘rm Antenna, Ml), Leonardo
`Antunitrlli. AID, Gianni (learia. MD. Maria I): Ciamu‘ln‘nn. AID, Carlo Lombardi. MD, brmmm RlI/II/II, 4WD.
`Guido Sat’rnlori. All). Dammn'a St'lviatrinu. All). and (iinnmrim henna. MD. Genoa, Ali/mt. Anemia.
`I'uriu.
`Chini. eria. Napier. Rome, and Fauna. Italy
`
`946
`
`A survey conducted by the authors found that a simplified sublingual immunothetapy
`(SLlT) schedule self-managed by the patient was characterized by a satisfactory
`compliance rate.
`
`Airway inflammation in occupational asthma caused by styrene
`Mar Ftrna'ndez-Ntrm. MD. Sdmmga Qmmv, MD, Pill). luau Fray. MD. Viaaria (lrl l’aza, I'M). Carmen 8mm.
`BSr. 3mm. Stunt, 85:. Carlos Lukas. MD. [’50. and Inaquiu 5mm. MD. I’lll). Madrid and Ztragnm.
`Spain
`
`948
`
`An autobody shop worker developed occupational asthma due to styrene exposure
`as confirmed by specific inhalation challenge and inflammatory changes in induced
`sputum.
`
`Prolonged elevation of serum tryptase in idiopathic anaphylaxis
`(Jam/I Slmmugam, MD. Laurent: If. Schwartz. MD. PhD. and David A. Khan. MI). Della. he. and Rid/11107141. V11
`
`950
`
`Serum tryptasc can be used to help diagnose idiopathic anaphylaxis even several hours after
`the onset of symptoms.
`
`Deep inhalation bronchoprotection in asthma: Correlation with airway
`responsiveness
`Donald W Lat-krrafl. MD. FRCI'KI). and [1th E. Davin;
`
`list: Satbuaon, Smlwrlvru-an. Canada
`
`951
`
`The deep inhalation protection of lironchoconstrietion induced by methachnlinc in mild
`asthma correlates with the underlying airway responsiveness, occurring only in those with
`methacholine PC 20 > 2mg/mL.
`
`Correspondence
`
`Cost-cflectiveness of home—based interventions should also take into account
`
`953
`
`nonrespiratory indoor health hazards
`Dem: Andre Charpm. MI). AII'H. Alanrr'lk. I-mnct
`
`Reply
`Alger Kmart. AID. Sully Stem-m, PIYD. Ellm Cram. 1WD. Cindy Vimm. MA. MI’H. and Hrnmm Alirrlvrll. PM).
`fiir (In lunn-(Iuy Asthma Srudy. Nrw York and Brain: N)2 and Chapel Hill. Nl ‘
`
`Nutritional supplements and pediatric upper respiratory tract illnesses
`Linda A. Liudqy. MD. New rant. N)’
`
`953
`
`953
`
` .
`
`1“ April 2006
`
`Page 9 of 16
`
`Continued on page 22A
`J ALLERGY CLIN IMMUNOL
`
`

`

`CONTENTS
`
`CONTINUED
`
`Reply
`Cur/Mm [let’rn‘mu .‘WD. :Im/ slur/mu) Newton,
`
`.Ul)‘ Aha/luv;
`
`l ‘lilffl’ Mug/14ml
`
`The difference between groups and individuals
`\cvd/ )Ag/Jm, 1/14 (7%! slurlrrio limb.
`'l/[l um/ I’ll/hill] I’qvma All), Inn/Inn.
`
`(I'm/171 King/{Inn
`
`Reply
`Arafat! dc Hit}: ”1).
`
`.lullllr/lr‘ I'u'lnvlrhiuud. .llli, I‘M). mm’ I'lrrrr firlvrlmmmu. ill/1 [firm and [II/:2 l’nmn'
`
`Viral specimen collection by parents increases response rate in
`population-based virus studies
`I‘MX Rum M [Jr/1mg. Ml). Hrnjy WEI/"min I'M).
`:llrlnrl‘r \! mu Ili‘rZr/m, .VD (,mmfi'
`I‘ .V ['nrrmrrry’, 1111)
`and ( arm-In A mm (in h”. All). I'lvl). ("Inn-lit .Iml BI/(lIm-ru.
`flu- .\'rtl'rrlimn’.-
`
`Reply
`Rob”! F erumkr, Ir.
`
`.\Il)‘_/i1um'
`
`/‘. (mm.
`
`.1”). and [humid F (Lillgmm. I’M), Madam:
`
`“"1:
`
`Environment—induced reactivity against autoallergcns: Possible role
`of latex
`I'll/ma): (;M.ll'ilr'll, Ill/1 Claudio (nmrm‘rl. MD. mn/Sd/mlurr Brnrnlgu Ml) flirniml. Ila/y
`
`The allergy archives: Pioneers and milestones
`
`l Henry Claman in profile
`Mrp/Irn (
`I’rrn’km,
`.U/J. [Vi/l [‘rm't’r (
`
`I'Ilf'
`
`if
`
`Identification of cellular cooperation in antibody production
`Charles II. Kirk/tannin ,‘ID. (firmer. Lulu
`
`¥ Thymocytes and bone marrow cells in I966: \X’liere did we go
`from there?
`
`I'le/r/Ipu .vllmmt'le. I'M). [)(mrr,
`
`(.m’n
`
`Beyond our pages
`Hum": /uvruumi.
`.\I[). and .lfmr I: Roi/vulirqu vl/ll l'lrll. hftmri
`
`Corrections
`
`Response to inhaled albuterol during nocturnal asthma
`IIIma'r/n It. But) It. Aim-n- It"
`\lr‘tru‘ (. um] Hilrm‘m [All Jon-1,] I i. Irhxvog.
`
`lnnate immunity For biodeknse: A strategy whose time has come
`I.‘l!ll[l(‘£¢:fl1nd C.
`l‘ : Drl. (aunt/{r .\l/'r Hu/Iuag/c (Ir/l. [hum KN ll‘lwim .\ It and ll 7r/uu HI
`3005:] [0:] ‘lj'd—dll
`
`954
`
`955
`
`955
`
`955
`
`956
`
`957
`
`959
`
`960
`
`962
`
`965
`
`773
`
`923
`
`(”unrimra/ on pace 23A
`
`J ALLERGY CLIN IMMUNOL
`
`
`
`22A April 2006
`
`Page 10 of 16
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`CONTENTS
`
`CONTINUED
`
`
`
`Reader services
`
`Instructions for authors
`Information for readers
`
`www.jacionline.org and January 2006, pages 23A-30A
`30A
`
`Newsview—American Academy of Allergy. Asthma and Immunology
`
`CME calendar—American Academy ofAllergy, Asthma and Immunology
`CME activities information
`
`Professional opportunities
`
`Change of address
`
`33A
`
`38A
`40A
`
`41A
`
`758
`
`
`
`is available to readers who successfully complete examinations
`Continuing Medical Education tCME) credit
`
`accompanying the aniclcs in the monthly series ('urrr-m Rn'ieua «(IA/[orgy and Clinical Immunology and Molecular
`
`Mechumxmr in Allergy and Clinical Immunology. This (”ME opponunity funhers the joint educational goals of the
`
`
`Journal and its sponsoring foundation. the American Academy of Allergy. Asthma and Immunology tAAAAI).
`Learning objectives. examination questions. and full details appear in each review article in the print and online Journal.
`The self-directed examinations can be taken at the JAC I website twww.jacionline.org). Credit is administered by the
`
`AAAAI.
`
`
`
`
`Complimentary I-year subscriptions to The Journal of Allergy and Clinical Immunology are available
`
`to AAAAI member FITS in the United States through an unrestricted educational grant from Alcon
`
`Laboratories. Inc.
`gr ,_
`7
`
`summits and opinions “pressed in the articles and minmunicaltom IICIL‘III an: those ol the authurts) and not neceuanly thmc ut the Editor. publisher. or the
`Andean Madcm) nl Allergy Asthma and Immunology The Editor. fluhllhhtl’. Hill the Aux-man Academy of Allergy. Asthma and Imtrrnnokm) til‘L‘IalIlI
`fly mainsihlllty or lluhllfl) [or such material and do not guarantee. warrant or endone an) product or \enrct- amt-nixed in this publication. not do the)
`"flier: any claim made by Ibr: nranulhttiirrr (if such [abduct or venue
`
`J ALLERGY CLlN IMMUNOL
`
`April 2006 23A
`
`Page 11 of 16
`
`

`

`Self-administration of C1-inhibitor concentrate
`
`in patients with hereditary or acquired
`angioedema caused by C1-inhibitor deficiency
`
`Marcel Levi, MD,‘ Goda Choi, MD,“ Charles Picavet, MA,b and C. Erik Hack, MD"
`“Hitlt'l'tICH/l. Tlir' N'i'I/ii'r/«Imli
`
`Backgmund: Administration of Cl-inhibitor concentrate is
`cffectitc for prophylaxis and treatment of severe angiocdcniu
`attacks caused by (‘I-inhibitor deficiency. The concentrate
`should be administered intrayenously and hence needs to be
`administered by health care professionals. which might cause
`considerable delay in treatment and inconienience for patients.
`()bjeetlye: The aim iif this study was to imestigate the
`
`feasibilir efficacy. and safety iif tin—demand and prophylactic
`self-administration of Cl~inhibitor concentrate in patients with
`frequent attacks of nogioedema.
`Methods: Patients with hereditary or acquired ('l-inhihitor
`deficiency who had sery frequent angioedema attacks were
`trained to self-administer ("l-inhibitor concentrate. The study
`consisted of 31 patients using tin-demand treatment and I2
`patiean using prophylaxis with (‘i-inhihitor concentrate.
`Mean follow-up was 3.5 years.
`Results: All patients were capable of self-administering the
`concentrate. with technical failure rates of self-injection being
`less than 2%. Times between the onset of the attack and the
`initiation of relief or complete resolution of symptoms in the
`tin-demand group were significantly shortened I2.2 hours and
`7.9 hours. respectively) «impaired with the situation before
`the start of self-administration. In the prophylaxis group
`«If-administration of (‘l-inhibitor concentrate decreased the
`angioedema attack rate from 4.0 to 0.3 attacks per month.
`Conclusion: Intravenous self-administration nf t'l-inhihitor
`concentrate is a feasible and safe option and results in more
`rapid and more effective treatment or prevention of severe
`angioedenia attacks in patients with t'i-inhibilor deficiency.
`Clinical implications: Self«administriition of (fl-inhibitor
`concentrate could be a valuable and convenient treatment
`modality to preterit or treat angioedema attacks in patients
`with (“l-inhibitor deficiency. (J Allergy (,‘lin Immuniit
`200ml ”MM-tin
`
`lhc
`
`l-rnm"tltcllcprinincnt ul Internal \lcdiciiie. Academic Meditnt (.'ciitcr.l tmei
`sity ol
`\nistcnlaiii
`"I‘hc \cthcrl.iiids Patient
`\ssociutinii ot
`llen-dit.ir\
`.\itti0c‘t|t:tttil .uid Quincic ~ Idciita. and 'ttic Luiilstciiict
`l.iitoiiitor\.
`\tmtcinic “mi